BACKGROUND: Regulatory T cells (Treg) are potentially a useful therapeutic option for the treatment of immunopathological conditions including graft-versus-host disease. Umbilical cord blood (UCB) offers certain advantages over adult peripheral blood (APB) as a source of Treg for cellular therapy but yields far fewer Treg per unit. Pooling of Treg from multiple donors may overcome this challenge. METHODS: In this study, we assessed the in vitro and in vivo efficacy of multiple donor pooled UCB or APB-derived Treg. RESULTS: In vitro, pooled freshly isolated UCB-derived Treg were as suppressive as APB-derived Treg. However, in a mouse model of human skin allodestruction, pooled UCB-derived Treg were more potent at suppressing alloresponses and prolonging skin survival compared with pooled APB-derived Treg. Improved survival of UCB Treg in an in vivo cell survival assay and their lower expression of human leukocyte antigen-ABC suggested that lower immunogenicity may account for their superior efficacy in vivo. CONCLUSION: Multiple-unit UCB is therefore a viable source of human Treg for cellular therapy, and pooling of Treg from multiple donors offers a useful strategy for achieving required therapeutic doses.
BACKGROUND: Regulatory T cells (Treg) are potentially a useful therapeutic option for the treatment of immunopathological conditions including graft-versus-host disease. Umbilical cord blood (UCB) offers certain advantages over adult peripheral blood (APB) as a source of Treg for cellular therapy but yields far fewer Treg per unit. Pooling of Treg from multiple donors may overcome this challenge. METHODS: In this study, we assessed the in vitro and in vivo efficacy of multiple donor pooled UCB or APB-derived Treg. RESULTS: In vitro, pooled freshly isolated UCB-derived Treg were as suppressive as APB-derived Treg. However, in a mouse model of human skin allodestruction, pooled UCB-derived Treg were more potent at suppressing alloresponses and prolonging skin survival compared with pooled APB-derived Treg. Improved survival of UCB Treg in an in vivo cell survival assay and their lower expression of human leukocyte antigen-ABC suggested that lower immunogenicity may account for their superior efficacy in vivo. CONCLUSION: Multiple-unit UCB is therefore a viable source of human Treg for cellular therapy, and pooling of Treg from multiple donors offers a useful strategy for achieving required therapeutic doses.
Authors: Catherine A Thornton; John W Upham; Matthew E Wikström; Barbara J Holt; Gregory P White; Mary J Sharp; Peter D Sly; Patrick G Holt Journal: J Immunol Date: 2004-09-01 Impact factor: 5.422
Authors: Vu H Nguyen; Robert Zeiser; Daniel L Dasilva; Daisy S Chang; Andreas Beilhack; Christopher H Contag; Robert S Negrin Journal: Blood Date: 2006-11-09 Impact factor: 22.113
Authors: Danila Valmori; Andrea Merlo; Naira E Souleimanian; Charles S Hesdorffer; Maha Ayyoub Journal: J Clin Invest Date: 2005-07 Impact factor: 14.808
Authors: Keli L Hippen; Paul Harker-Murray; Stephen B Porter; Sarah C Merkel; Aryel Londer; Dawn K Taylor; Megan Bina; Angela Panoskaltsis-Mortari; Pablo Rubinstein; Nico Van Rooijen; Tatiana N Golovina; Megan M Suhoski; Jeffrey S Miller; John E Wagner; Carl H June; James L Riley; Bruce R Blazar Journal: Blood Date: 2008-07-21 Impact factor: 22.113
Authors: Jorieke H Peters; Frank W Preijers; Rob Woestenenk; Luuk B Hilbrands; Hans J P M Koenen; Irma Joosten Journal: PLoS One Date: 2008-09-08 Impact factor: 3.240